IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market following confirmation from the Nasdaq Hearings Panel. As a result, IMUNON common stock will continue uninterrupted trading on The Nasdaq Capital Market.
Related Questions
How will the regained compliance affect IMNNâs shortâterm price volatility and liquidity on Nasdaq?
Does this listing event change market perception of IMUNONâs operational stability versus its peers in the biotech sector?
What are the potential downstream effects on upcoming clinicalâtrial milestones and financing needs now that Nasdaq delisting risk is removed?